Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

In a previous study, we identified somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in patients with myelodysplastic syndrome (MDS). Here, we define the clinical significance of these mutations in MDS and myelodysplastic/myeloproliferative neoplasms (MDS/MPN)....

Bibliografski detalji
Glavni autori:	Malcovati, L, Papaemmanuil, E, Bowen, D, Boultwood, J, Della Porta, MG, Pascutto, C, Travaglino, E, Groves, M, Godfrey, A, Ambaglio, I, Gallì, A, Vià, D, Conte, S, Tauro, S, Keenan, N, Hyslop, A, Hinton, J, Mudie, L, Wainscoat, J, Futreal, P, Stratton, MR, Campbell, P, Hellström-Lindberg, E, Cazzola, M
Format:	Journal article
Jezik:	English
Izdano:	2011

Slični predmeti

Myelodysplastic/myeloproliferative disorders
od: Luca Malcovati, i dr.
Izdano: (2008-01-01)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
od: Luca Malcovati, i dr.
Izdano: (2014-11-01)

Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
od: Mario Cazzola
Izdano: (2011-03-01)

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool
od: Matteo G. Della Porta, i dr.
Izdano: (2012-04-01)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
od: Pellagatti, A, i dr.
Izdano: (2009)

Clonality in the myelodysplastic syndromes.
od: Boultwood, J, i dr.
Izdano: (2001)

Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts
od: Malcovati, L, i dr.
Izdano: (2011)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
od: Pellagatti, A, i dr.
Izdano: (2010)

Molecular basis of myelodysplastic/myeloproliferative neoplasms
od: Andreas Reiter, i dr.
Izdano: (2009-12-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
od: Pellagatti, A, i dr.
Izdano: (2010)

Molecular pathogenesis of the myelodysplastic syndromes
od: Boultwood, J, i dr.
Izdano: (1999)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
od: Pellagatti, A, i dr.
Izdano: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
od: Pellagatti, A, i dr.
Izdano: (2011)

Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders
od: Zhang, J, i dr.
Izdano: (2004)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
od: Pellagatti, A, i dr.
Izdano: (2008)

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
od: Matteo G. Della Porta, i dr.
Izdano: (2011-03-01)

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
od: Papaemmanuil, E, i dr.
Izdano: (2013)

MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES
od: I. N. Subortseva, i dr.
Izdano: (2017-01-01)

Telomere length in myelodysplastic syndromes.
od: Boultwood, J, i dr.
Izdano: (1995)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
od: Pellagatti, A, i dr.
Izdano: (2009)

Myelodysplastic syndromes
od: Eva Hellström Lindberg
Izdano: (2018-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
od: Pellagatti, A, i dr.
Izdano: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
od: Pellagatti, A, i dr.
Izdano: (2010)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
od: Boultwood, J, i dr.
Izdano: (2009)

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
od: Luca Malcovati, i dr.
Izdano: (2011-10-01)

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic
od: Papaemmanuil, E, i dr.
Izdano: (2012)

Identification of aberrant splicing events in myelodysplastic syndrome patients with splicing factor gene mutations
od: Pellagatti, A, i dr.
Izdano: (2017)

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
od: Pellagatti, A, i dr.
Izdano: (2013)

Gene expression profiling in the myelodysplastic syndromes.
od: Pellagatti, A, i dr.
Izdano: (2005)

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1
od: Ilaria Ambaglio, i dr.
Izdano: (2013-03-01)

Genome sequencing in the management of myelodysplastic syndromes and related disorders
od: Mario Cazzola, i dr.
Izdano: (2024-10-01)

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE IN MYELODYSPLASTIC SYNDROMES - REPLY
od: Boultwood, J, i dr.
Izdano: (1991)

COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
od: Pellagatti, A, i dr.
Izdano: (2014)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
od: Boultwood, J, i dr.
Izdano: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes
od: Pellagatti, A, i dr.
Izdano: (2007)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
od: Ziqi Wan, i dr.
Izdano: (2020-10-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
od: Pellagatti, A, i dr.
Izdano: (2005)

Genome-wide analysis of copy number change and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density SNP arrays
od: Wang, L, i dr.
Izdano: (2007)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
od: Michael J. Hochman, i dr.
Izdano: (2021-08-01)

Myelodysplastic and myeloproliferative diseases in children: current concepts
od: Vyas, P
Izdano: (2014)